Biotechnology
Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
CASTRES, France, CAMBRIDGE, Massachusetts and BASEL, Switzerland, March 12, 2025 /PRNewswire/ -- Pierre Fabre Laboratories and RedRidge Bio ("RedRidge") today announced an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody (BPA) drug candidates against ...
2025-03-12 17:00
2190
Caliway's CBL-514 Phase 2 Study (CBL-0202) Accepted for Publication in the Aesthetic Surgery Journal
Advancing Scientific Recognition in Non-Surgical Fat Reduction * Caliway's CBL-514 Phase 2 study (CBL-0202) has been accepted for publication inAesthetic Surgery Journal (ASJ), the top-ranked journal in aesthetic medicine and plastic surgery. * Clinical data (ITT population) showed that over ...
2025-03-12 14:29
2088
WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs
SHANGHAI and SEOUL, South Korea , March 11, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates...
2025-03-11 21:20
2022
WuXi Biologics Included in S&P Global Sustainability Yearbook 2025
* Ranking in top 1% of S&P Global CSA Score * Inclusion in Global Yearbook for third consecutive year * Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Develop...
2025-03-11 11:18
2879
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...
2025-03-11 08:00
1848
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...
2025-03-11 08:00
1944
TCI Biotech Announces Strong 2024 Financial Performance, Sets Sights on Global Growth in 2025
TAIPEI, March 10, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.) (TWSE: 8436), a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year endingDecember 31, 2024. The company reported steady revenue performance, stron...
2025-03-10 23:00
2733
SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing
SINGAPORE and NEW YORK, March 10, 2025 /PRNewswire/ -- SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services based inSingapore, and One Investment Management ("OneIM"), a global alternative investment management firm, today ann...
2025-03-10 20:19
2503
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...
2025-03-10 19:22
1946
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, March 9, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers,today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...
2025-03-10 10:53
1998
RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH) Phase I/...
2025-03-10 09:30
2387
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
* OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by theFDA * Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] * The ava...
2025-03-10 07:16
2449
Nona Biosciences Integrates Cutting-Edge AI Technology to Enhance Its Fully Human Antibody Platform, Accelerating Antibody Discovery Across Key Therapeutic Areas
CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), today announced to unveil its innovative AI-assisted drug discovery engine, Hu-mAtrIxTM. This new platform, powered by advanced artificial ...
2025-03-07 14:00
1914
GenAssist Ltd Announces FDA Clearance of Investigational New Drug Application for GEN6050X, a Globally First-in-Class Base Editing Drug for Duchenne Muscular Dystrophy
SUZHOU, China, March 6, 2025 /PRNewswire/ -- On March 06, 2025, GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has receivedclearance from the U.S Food and Drug Administration(FDA) for its Investigational...
2025-03-06 17:00
1727
Everest Medicines Announces First Patient Dosed with EVM16, Its First Internally Developed Personalized mRNA Cancer Vaccine
* The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials. * In preclinical studies, EVM16 demonstrated...
2025-03-06 16:30
2281
Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics
SINGAPORE, March 6, 2025 /PRNewswire/ -- In a significant development for the clinical diagnostics landscape inSingapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to formArcherfish Precision Diagnostics Private Limited (...
2025-03-06 11:52
2088
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific antibod...
2025-03-06 08:30
2195
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative cancer therapy based on membrane lipid therapy, announced today optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma ...
2025-03-05 22:45
1919
Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director
ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend)
2025-03-05 22:33
2461
Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics
SINGAPORE, March 5, 2025 /PRNewswire/ -- In a significant development for the clinical diagnostics landscape inSingapore, Angsana Molecular & Diagnostics Laboratory (Angsana) and Pathnova Laboratories (Pathnova) have announced their merger to formArcherfish Precision Diagnostics Private Limited (...
2025-03-05 22:00
2433
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 281 media titles]
2026-01-07 10:00
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Space Summit 2026 to Convene Global Leaders in Singapore to Address the Growing Space Economy
[Picked up by 271 media titles]
2026-01-07 15:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
8863
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
8069
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7447
